February 28, 2018 / 12:42 PM / 10 months ago

BRIEF-Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease

Feb 28 (Reuters) - Sangamo Therapeutics Inc:

* SANGAMO ANNOUNCES U.K. AUTHORIZATION OF CLINICAL TRIAL EVALUATING ZINC FINGER NUCLEASE IN VIVO GENOME EDITING TREATMENT FOR HEMOPHILIA B

* SANGAMO THERAPEUTICS INC - EXPECTS TO INITIATE SITES IN U.K. LATER THIS YEAR FOR SB-FIX PHASE 1/2 CLINICAL TRIAL​

* SANGAMO THERAPEUTICS INC - ‍EXPECTS TO FILE ADDITIONAL CTAS FOR SB-318 & SB-913 IN VIVO GENOME EDITING TREATMENTS FOR MPS I AND MPS II, RESPECTIVELY​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below